Introduction {#s0001}
============

The degradation and recycling of intracellular components is crucial for the maintenance of cellular or tissue homeostasis. The lysosome, a membrane-bound acidic organelle, plays a pivotal role in the degradation of biological macromolecules such as proteins, lipids, carbohydrates and nucleic acids, and organelles. The transport of intracellular components into lysosomes occurs via autophagy, which has been described as a self-eating catabolic process.[@cit0001] At least 3 different types of autophagy have been identified to date: macroautophagy; microautophagy; and chaperone-mediated autophagy (CMA).[@cit0001]

CMA is a pathway in which cytosolic substrate proteins are directly transported into lysosomes, in an ATP- and HSPA8 (heat shock protein family A \[Hsp70\] member 8) chaperone-dependent manner, and degraded.[@cit0002] In this pathway, LAMP2A (lysosomal-associated membrane protein 2A), the product of one of 3 splice variants of the *LAMP2* gene (*LAMP2A*, *LAMP2B* and *LAMP2C*) acts as a receptor for cytoplasmic substrate proteins. In addition to these pathways, we discovered a novel and selective type(s) of autophagy that targets RNA and DNA, which we designated RNautophagy and DNautophagy, respectively.[@cit0003] In these pathways, nucleic acids are directly taken up by lysosomes in an ATP-dependent manner and degraded. We found that LAMP2C can act as a receptor for nucleic acids.[@cit0003] Additionally, we have recently reported that RNautophagy and DNautophagy possesses selectivity for RNA and DNA substrates, respectively.[@cit0006] However, the mechanism by which substrate nucleic acids are translocated across the lysosomal membrane and the physiological role of RNautophagy and DNautophagy remain unclear.

In the present study, we sought to identify any proteins that mediate translocation of nucleic acids into lysosomes. We found that SIDT2 (SID1 transmembrane family, member 2), an ortholog of the *Caenorhabditis elegans* putative RNA transporter SID-1 (systemic RNA interference deficient-1), mediates translocation of RNA into lysosomes during RNautophagy. We confirmed that SIDT2 predominantly localizes to lysosomes. We also showed that knockdown of *Sidt2* inhibits ˜50% of total RNA degradation in wild-type (WT) mouse embryonic fibroblasts (MEFs), strongly suggesting that RNautophagy plays a significant role in constitutive cellular RNA degradation.

Results {#s0002}
=======

SIDT2 is a transmembrane protein that predominantly localizes to lysosomes {#s0002-0001}
--------------------------------------------------------------------------

Candidate lysosomal proteins that might translocate RNA or DNA were identified using the AmiGO gene ontology database,[@cit0007] which was designed for the standardization of gene product attributes across species. According to AmiGO, the SID-1 family proteins (SID-1, SIDT1 \[SID1 transmembrane family, member 1\] and SIDT2) are the only group of putative RNA-specific transporters. *Caenorhabditis elegans* SID-1 protein has been reported to transport extracellular double-stranded RNA (dsRNA) into cells.[@cit0008] SID-1 is a multipass transmembrane protein and partly localizes to the plasma membrane.[@cit0008] An electrophysiological study suggested that SID-1 functions as a bidirectional channel for dsRNA.[@cit0009] Mammals have 2 SID-1 orthologs, SIDT1 and SIDT2. SIDT1 has been reported to localize to the plasma membrane of human cells and to mediate bidirectional transport of RNA.[@cit0010] Human SIDT1 is predominantly expressed in dendritic cells and lymphocytes,[@cit0012] whereas SIDT2 is almost ubiquitously expressed.[@cit0012] Although multiple studies have reported that SIDT2 is a membrane protein which mainly localizes to lysosomes,[@cit0013] its role on the lysosomal membrane remains unclear. To confirm the lysosomal localization of SIDT2, we isolated lysosomes from the mouse brain using a method described previously.[@cit0003] Analysis of lysosome content showed that SIDT2 is enriched in the lysosomal fraction that is positive for LAMP2, a lysosomal marker ([Fig. 1A](#f0001){ref-type="fig"}), indicating that endogenous SIDT2 localizes to lysosomes. We confirmed that other organelle markers are not enriched in the lysosomal fraction ([Fig. 1A](#f0001){ref-type="fig"}). In addition, electron microscopy revealed that the lysosomal fraction is rich in electron-dense lysosomes (primary lysosomes), and we could not find any other intact organelles, such as late endosomes, in the lysosomal fraction (Fig. S1). For further confirmation of the lysosomal localization of SIDT2, we examined its localization using a C-terminal GFP-tag in Neuro2a murine cells, where lysosomal compartments are clearly observable with LysoTracker Red. Fluorescent signals for SIDT2 were detected in lysosomes, which were stained with LysoTracker Red ([Fig. 1B](#f0001){ref-type="fig"}). In contrast, colocalization rates of SIDT2 with RAB7A (RAB7A, member RAS oncogene family; a late endosomal and lysosomal marker), EEA1 (early endosome antigen 1; an early endosomal marker) or MAP1LC3A/B (microtubule associated protein 1 light chain 3 α/β an autophagosomal marker) were very low ([Fig. 1C](#f0001){ref-type="fig"}), indicating that SIDT2 is not primarily localized to early and late endosomes, or autophagosomes. Considering that there are RAB7A-positive and -negative lysosomes,[@cit0016] our results also indicate that SIDT2 does not mainly localize to RAB7-positive lysosomes. By using a transmembrane protein topology prediction method based on a hidden Markov model (TMHMM 2.0), SIDT2 was predicted to possess 9 transmembrane domains (Fig. S2). To test for the localization of SIDT2 on the lysosomal membrane, we performed a trypsin digestion of membrane proteins of lysosomes isolated from cells expressing FLAG-tagged SIDT2. As shown in [Fig. 1D](#f0001){ref-type="fig"}, SIDT2-FLAG was digested by trypsin in a dose-dependent manner. We confirmed that FLAG-tagged CTSB (cathepsin B), which is a known lysosomal lumenal protein, was not affected by trypsin treatment ([Fig. 1D](#f0001){ref-type="fig"}). Our results, taken together with the previous reports,[@cit0013] indicate that SIDT2 is a lysosomal membrane protein. Figure 1.Characterization of SIDT2. (A) Lysosomes (Lys) were isolated from mouse brain homogenates (Hom), and analyzed by immunoblotting using polyclonal goat anti-SIDT2 antibody and antibodies against LAMP2 (lysosomal marker), RAB7A (late endosome and lysosome), RAB5A (early endosome), CANX (endoplasmic reticulum), COX4I1 (mitochondria), GOLGA1 (Golgi apparatus), GAPDH (cytosol), LMNA/lamin A (nuclei), and MAP1LC3A/B (autophagosome). (B) Neuro2a cells expressing GFP-tagged SIDT2 were incubated with LysoTracker Red. Fluorescence images were visualized using a confocal laser-scanning microscope. Scale bar: 10 μm. Colocalization rate was quantified using ImageJ software (right panel, n = 3). (**C**) Neuro2a cells expressing GFP-tagged SIDT2 were fixed, and immunostained using anti-RAB7A, anti-EEA1 (early endosomal marker) or anti-MAP1LC3A/B antibodies. Fluorescent images were obtained using confocal microscopy. Scale bars: 5 μm. Colocalization rate was quantified (right panels, n = 3). (D) Lysosomes were isolated from HeLa cells expressing SIDT2-FLAG or CTSB-FLAG. Isolated lysosomes (4 μg protein) were incubated with the indicated concentrations of trypsin at 37°C for 5 min. Proteins in the samples were analyzed by immunoblotting using an anti-FLAG antibody. (E) LAMP2C and SIDT2 or SIDT2-FLAG were overexpressed in HeLa cells. Cell lysates were prepared and immunoprecipitated with an anti-FLAG antibody. Cell lysates and the resulting immunoprecipitant were analyzed by immunoblotting. (F) Lysates were prepared from HeLa cells overexpressing SIDT2 and LAMP2C or LAMP2C-FLAG and coimmunoprecipitation assays performed. (G) Endogenous interaction of SIDT2 with LAMP2C. Coimmunoprecipitation assays were performed using mouse brain lysates. (H) Neuro2a cells coexpressing FLAG-tagged LAMP2C and GFP-tagged SIDT2 were fixed, and immunostained using anti-FLAG antibody. Scale bars: 10 μm. Colocalization rate was quantified (right panel, n = 3).

SIDT2 interacts with LAMP2C {#s0002-0002}
---------------------------

We have previously shown that LAMP2C can function as a lysosomal membrane receptor for nucleic acids during RNautophagy and DNautophagy.[@cit0003] We examined the interaction of SIDT2 with LAMP2C by cotransfecting HeLa cells with vectors that expressed FLAG-tagged SIDT2 and untagged LAMP2C, and analyzed cell lysates by coimmunoprecipitation with an anti-FLAG antibody. Coimmunoprecipitation of LAMP2C with SIDT2 indicated an interaction between these proteins ([Fig. 1E](#f0001){ref-type="fig"}). Similar experiments using untagged SIDT2 and FLAG-tagged LAMP2C confirmed the interaction between these proteins ([Fig. 1F](#f0001){ref-type="fig"}). To assess endogenous interaction in vivo, a coimmunoprecipitation assay was performed using mouse whole brain lysates, showing the interaction between endogenous SIDT2 and endogenous LAMP2C ([Fig. 1G](#f0001){ref-type="fig"}). We observed that SCARB2/LIMP2 (scavenger receptor class B, member 2), another lysosomal membrane protein, was not precipitated with SIDT2 ([Fig. 1G](#f0001){ref-type="fig"}), confirming that the interaction between SIDT2 and LAMP2C is not a nonspecific interaction. Whether this interaction is direct or indirect is unclear. Colocalization of SIDT2 and LAMP2C was also observed ([Fig. 1H](#f0001){ref-type="fig"}). These results taken together with the lysosomal localization of SIDT2, and the known function of SID-1 or SIDT1 as mediators of bidirectional RNA transport, led to the hypothesis that SIDT2 is involved in the translocation of RNA during RNautophagy.

Overexpression of SIDT2 enhances RNA uptake and degradation in isolated lysosomes {#s0002-0003}
---------------------------------------------------------------------------------

To investigate whether SIDT2 mediates translocation of RNA in the process of RNautophagy, we performed gain- and loss-of-function studies combined with RNA uptake and degradation assays. Uptake and degradation of RNA was assessed in isolated lysosomes using a method reported previously.[@cit0003] Isolated lysosomes and RNA were incubated with ATP, lysosomes were precipitated by centrifugation, and RNA levels remaining in the solution outside of lysosomes were analyzed as an indicator of RNA uptake activity[@cit0003] ([Fig. 2A](#f0002){ref-type="fig"}). RNA uptake activity was also assessed by incubating lysosomes with RNA and ATP, degrading RNA outside of lysosomes with exogenous ribonuclease A (RNase A), and then analyzing the levels of RNase A-resistant RNA, which corresponds to RNA inside lysosomes ([Fig. 2A](#f0002){ref-type="fig"}). Furthermore, RNA uptake activity was confirmed using postembedding immunoelectron microscopy. Figure 2.Effects of SIDT2 overexpression on RNA uptake and degradation by lysosomes. (A and B) Outlines of RNA uptake assays (A) and RNA degradation assays (B) using isolated lysosomes. (C) SIDT2 was overexpressed in Neuro2a cells. Protein levels were analyzed by immunoblotting using a goat anti-SIDT2 antibody. (D) The RNA uptake assay I indicated in (A) was performed using 5 μg of total RNA derived from mouse brains and isolated lysosomes derived from cells overexpressing SIDT2, or from control cells transfected with empty vector. Relative RNA levels in the solution outside lysosomes were quantified, and levels of RNA uptake were measured by subtracting RNA levels remaining in solution outside lysosomes from RNA input levels. Mean values are shown with SEM (*n* = 3). \*\*\*, *P* \< 0.001. (E) RNA uptake assay II was performed as indicated in (A). Relative levels of RNA resistant to exogenous RNase A were analyzed. Mean ± SEM (*n* = 3). \*, *P* \< 0.05. (F) Isolated lysosomes were incubated with RNA and ATP as indicated in (A). Post-embedding immunoelectron microscopy was performed using an anti-rRNA antibody followed by anti-mouse IgG coupled with 10-nm gold particles. Gold particles were observed in the lysosomes. The numbers of gold particles per lysosome were counted. Mean ± SD (*n* = 25). \*\*\*, *P* \< 0.001. Scale bars: 200 nm. (G) RNA degradation assays were performed as indicated in (B). Total RNA levels in samples were quantified, and levels of RNA degradation were measured by subtracting the RNA levels remaining in samples from the levels of input RNA. Mean ± SEM (*n* = 3). \*\*\*, *P* \< 0.001. (H) Degradation of various RNAs by isolated lysosomes. RNA degradation assays were performed as described in [Fig. 2B](#f0002){ref-type="fig"}. Relative levels of RNAs in samples were measured by qPCR analyses. Mean values are shown with SEM (n = 3). *Actb*, β-actin. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001, n.s., not significant (Tukey test or Fisher LSD test). (**I**) Degradation of 28S and 18S rRNAs by isolated lysosomes. RNA degradation assays were performed using total RNA that does not contain small RNAs (under 200 bases). Undegraded and partially degraded RNAs were visualized using ethidium bromide staining (left). Relative levels of rRNAs (28S and 18S) were quantified, and levels of RNA degradation were measured by subtracting the RNA remaining in samples from the levels of input RNA (middle). Relative levels of partially degraded RNAs were quantified (right). Mean values are shown with SEM (n = 3). \*\*, *P* \< 0.01. (**J**) RNAs were not degraded in the solution outside of lysosomes. Isolated lysosomes were incubated with ATP for 5 min at 37°C. The lysosomes were removed by centrifugation, and the solution outside lysosomes was incubated with 5 μg of total RNA for 5 min at 37°C. Mean values are shown with SEM (n = 3). n.s., not significant. RNAs were visualized by ethidium bromide staining. (K) RNA degradation by lysed lysosomes. Isolated lysosomes were lysed in citrate-phosphate buffer (pH 5.0) containing 1% Triton X-100, mixed with 5 μg of total RNA, and incubated for 5 min at 37°C. Mean values are shown with SEM (n = 3). n.s., not significant. (L) Absence of RNA in isolated lysosomes incubated without exogenous RNA. Isolated lysosomes were incubated without exogenous RNA in the presence of ATP for 5 min at 37°C. (M) ATP requirement of RNautophagy. RNA degradation assays were performed in the absence of ATP. Total RNA levels in samples were quantified. Mean values are shown with SEM (n = 3). n.s., not significant.

We incubated isolated lysosomes and RNA in the presence of ATP and analyzed the total RNA level in samples as an indicator of whether RNA is degraded in lysosomes[@cit0003] ([Fig. 2B](#f0002){ref-type="fig"}). RNA degradation also indicates the uptake of RNA, because RNA is not degraded in the solution outside of lysosomes.[@cit0003]

To investigate the effects of SIDT2 overexpression on RNA uptake ability, Neuro2a cells were transfected with an expression vector that produced untagged full-length SIDT2 ([Fig. 2C](#f0002){ref-type="fig"}). Lysosomes were isolated, and RNA uptake and degradation assays were performed. Lysosomes isolated from SIDT2-overexpressing cells had a significantly higher RNA uptake activity than those transfected with the control empty vector ([Fig. 2D--E](#f0002){ref-type="fig"}). The higher RNA uptake activity of lysosomes derived from SIDT2-overexpressing cells was confirmed using post-embedding immunoelectron microscopy ([Fig. 2F](#f0002){ref-type="fig"}, Fig. S3).

Additionally, a significant enhancement of RNA degradation was observed in lysosomes isolated from SIDT2-overexpressing cells ([Fig. 2G](#f0002){ref-type="fig"}). Although 28S and 18S rRNAs were clearly degraded, levels of smear bands also appeared to be decreased in the degradation assay ([Fig. 2G](#f0002){ref-type="fig"}), suggesting that RNAs besides 28S and 18S rRNAs are also degraded by isolated lysosomes. To test this possibility, we selected 3 mRNAs \[*Actb* (actin, β)/β-actin, *Gapdh* (glyceraldehyde-3-phosphate dehydrogenase) and *Uchl1* (ubiquitin carboxyl-terminal hydrolase L1)\], which are expressed in mouse brains, and analyzed their relative levels by quantitative PCR. Levels of 5S and 5.8S rRNAs were also analyzed. As a result, mRNAs, 5S and 5.8S rRNAs were all degraded by lysosomes, and overexpression of SIDT2 enhanced the degradation ([Fig. 2H](#f0002){ref-type="fig"}). We also tested the degradation of purified total RNA that does not contain small RNAs. The degradation of 28S and 18S RNAs was enhanced by SIDT2 overexpression, and the levels of partially degraded RNA were increased by SIDT2 overexpression ([Fig. 2I](#f0002){ref-type="fig"}). This indicates that the small size RNA within the lysosomes shown in [Fig. 2E](#f0002){ref-type="fig"} contains partially degraded RNA. We confirmed that RNA was not degraded in the solution outside of lysosomes derived from either SIDT2-overexpressing or control cells ([Fig. 2J](#f0002){ref-type="fig"}). RNA was degraded in the solution containing disrupted lysosomes derived from either SIDT2-overexpressing or control cells ([Fig. 2K](#f0002){ref-type="fig"}), confirming that RNA degradation occurred inside lysosomes. Overexpression of SIDT2 did not affect lysosomal nuclease activities because it did not alter the levels of RNA degradation in the disrupted lysosomes ([Fig. 2K](#f0002){ref-type="fig"}), nor lysosomal pH (Fig. S4). We also observed that no RNA was detected in the isolated lysosomes incubated without exogenous RNA ([Fig. 2L](#f0002){ref-type="fig"}), confirming that the RNA detected in uptake and degradation assays is derived from exogenous RNA. These results indicate that overexpression of SIDT2 enhances lysosomal uptake of RNA, leading to elevated levels of RNA degradation by lysosomes.

When ATP was not added to isolated lysosomes, evidence of RNA uptake activity was absent in lysosomes derived from SIDT2 overexpressing and control cells ([Fig. 2M](#f0002){ref-type="fig"}). Therefore, SIDT2-mediated uptake of RNA appears to be ATP-dependent, consistent with observations that RNautophagy is ATP-dependent. Overexpression of SIDT2 increased RNA uptake activity in another cell line, NIH/3T3, in which transfection yielded a 2-fold increase in SIDT2 expression levels compared with endogenous levels (Fig. S5A and B).

We investigated the relationship between SIDT2 and LAMP2C during RNautophagy. We tested the effect of SIDT2 overexpression on RNA transport activity in lysosomes derived from *LAMP2*-deficient cells. Overexpression of SIDT2 increased RNautophagy even in *LAMP2*-deficient lysosomes ([Fig. 3A--C](#f0003){ref-type="fig"}), indicating that SIDT2 is able to function independently of LAMP2C. This result is consistent with our previous report showing that LAMP2 is not indispensable for RNautophagy.[@cit0003] Figure 3.Effect of SIDT2 overexpression on RNautophagy in the absence of LAMP2. (A) LAMP2 levels in *LAMP2*-deficient HeLa cells and parental HeLa cells (control HeLa) were analyzed by immunoblotting. (B and C) RNA uptake assays were performed using isolated lysosomes derived from *LAMP2*-deficient HeLa cells (B) or parental HeLa cells (C). Relative levels of RNA uptake were quantified. Results are expressed as mean ± SEM (*n* = 3). \*\*, *P* \< 0.01. In the absence of LAMP2, SIDT2 increased RNautophagy at similar levels to in the presence of LAMP2.

Shih and Hunter report that the S536I mutant SID-1, which is found in a systemic RNA interference-deficient mutant in *Caenorhabditis elegans*,[@cit0019] lacks RNA translocation function,[@cit0008] and the Ser536 of SID-1 corresponds to Ser564 of mouse SIDT2 (Fig. S6). Therefore, we speculated that a mutation at Ser564 inhibits lysosomal RNA uptake by SIDT2. We constructed a S564A mutant SIDT2, and tested the effects of this mutation on RNA uptake by lysosomes. We observed that SIDT2^S564A^ localizes to lysosomes as readily as WT SIDT2 ([Fig. 4A--B](#f0004){ref-type="fig"}), and that the mutation does not affect the interaction with LAMP2C ([Fig. 4C](#f0004){ref-type="fig"}). In contrast to WT SIDT2, however, overexpression of SIDT2^S564A^ did not increase RNautophagy ([Fig. 4D](#f0004){ref-type="fig"}), indicating that functional SIDT2 protein is required to import RNAs into lysosomes. Taken together, our results support the notion that SIDT2 mediates RNA translocation during RNautophagy. Figure 4.Effect of SIDT2 mutation on RNautophagy. (A) Neuro2a cells expressing GFP-tagged SIDT2^S564A^ were incubated with LysoTracker Red. Fluorescence images were visualized using a confocal laser-scanning microscope. Scale bar: 10 μm. Colocalization rate was quantified (right panel, n=3). (B and D) Lysosomes were isolated from Neuro2a cells overexpressing WT or mutant SIDT2^S564A^ or control transfectants. SIDT2 levels in lysosomes were analyzed by immunoblotting (B). The RNA uptake assay I indicated in [Fig. 2A](#f0002){ref-type="fig"} was performed (D). Relative levels of RNA uptake were quantified. Mean ± SEM (*n* = 3). \*\*\*, *P* \< 0.001. (**C**) LAMP2C or LAMP2C-FLAG and WT or mutant SIDT2^S564A^ were overexpressed in Neuro2a cells. Cell lysates were prepared and immunoprecipitated with an anti-FLAG antibody. Cell lysates and the resulting immunoprecipitant were analyzed by immunoblotting.

Knockdown of SIDT2 impairs RNA uptake and degradation in isolated lysosomes {#s0002-0004}
---------------------------------------------------------------------------

To investigate the effects of *SIDT2* knockdown on RNautophagy activity, HeLa cells were transfected with siRNAs targeting *SIDT2*. Lysosomes were isolated and RNA uptake assays were performed. Lysosomes isolated from *SIDT2* knockdown cells showed significantly lower RNA uptake than lysosomes from control siRNA-transfected cells ([Fig. 5A--B](#f0005){ref-type="fig"}). A significant reduction of RNA degradation was observed in lysosomes isolated from *SIDT2* knockdown cells ([Fig. 5C](#f0005){ref-type="fig"}). Similar results were obtained when we used another siRNA against *SIDT2* ([Fig. 5D--F](#f0005){ref-type="fig"}). We confirmed that knockdown of *SIDT2* did not affect lysosomal pH (Fig. S4). The impairment of RNA uptake and degradation by *SIDT2* knockdown was also confirmed in the 293FT cell line (Fig. S7). Collectively, these results demonstrate that SIDT2 is a critical determinant of RNautophagy activity. Figure 5.Effects of *SIDT2* knockdown on RNA uptake and degradation by lysosomes. (A and D) Decreased levels of SIDT2 proteins in HeLa cells transfected with *SIDT2*-siRNA were confirmed by immunoblotting. Relative levels of SIDT2 were quantified. Results are expressed as mean ± SEM (*n* = 3). (B and E) RNA uptake assay I ([Fig. 2A](#f0002){ref-type="fig"}) was performed using isolated lysosomes derived from *SIDT2* knockdown or control siRNA-transfected cells. Relative levels of RNA uptake were quantified. Mean ± SEM (*n* = 3). \*\*\*, *P* \< 0.001. (C and F) RNA degradation assay using lysosomes isolated from *SIDT2*-knockdown cells or from control cells. Relative levels of RNA degradation were quantified. Mean ± SEM (*n* = 3). \*\*\*, *P* \< 0.001; \*\*, *P* \< 0.01.

SIDT1 is not involved in RNautophagy {#s0002-0005}
------------------------------------

We investigated whether or not SIDT1 is involved in RNautophagy. We examined intracellular localization of SIDT1 using a C-terminal GFP-tag. Fluorescent signals for SIDT1 scarcely colocalized with LysoTracker Red ([Fig. 6A](#f0006){ref-type="fig"}). In addition, overexpression of SIDT1 did not affect RNautophagy in RNA uptake assays ([Fig. 6B--C](#f0006){ref-type="fig"}). Thus, in contrast to SIDT2, SIDT1 does not function in RNautophagy. Figure 6.Effect of SIDT1 overexpression on RNautophagy. (A) Neuro2a cells expressing GFP-tagged SIDT1 were incubated with LysoTracker Red. Fluorescence images were visualized using a confocal laser-scanning microscope. Scale bar: 10 μm. Colocalization rate was quantified (right panel, n=3). (B) SIDT1 was overexpressed in Neuro2a cells. Protein levels were analyzed by immunoblotting using an anti-SIDT1 antibody. (C) Lysosomes were isolated from Neuro2a cells overexpressing SIDT1 or control transfectants. The RNA uptake assay I indicated in [Fig. 2A](#f0002){ref-type="fig"} was performed. Relative levels of RNA uptake were quantified. Mean ± SEM (*n* = 3). n.s., not significant.

Sidt2 knockdown impairs cellular RNA degradation {#s0002-0006}
------------------------------------------------

A constitutive degradation of cellular components or proteins is one of the most important physiological roles of both macroautophagy and CMA.[@cit0001] To determine whether endogenous SIDT2 plays a role in RNA degradation at the cellular level, endogenous RNA was labeled with \[^3^H\]-uridine in *Sidt2* knockdown cells or control siRNA-transfected cells. The levels of labeled RNA in cells were measured at 0, 6 and 24 h ([Fig. 7A, upper panel](#f0007){ref-type="fig"}), with labeled RNA levels normalized to total protein levels. To exclude the involvement of macroautophagy, we performed pulse-chase experiments using the macroautophagy deficient *atg5* (autophagy-related 5)-knockout (KO) MEFs. Our results show that RNA degradation was impaired in *Sidt2* knockdown cells compared with that in control cells ([Fig. 7B--C](#f0007){ref-type="fig"}). We confirmed that the conversion of MAP1LC3A/B-I to MAP1LC3A/B-II was not observed in *atg5* KO MEFs ([Fig. D](#f0007){ref-type="fig"}). To confirm that the effects of *Sidt2*-knockdown on radioactive uridine are due to impaired lysosomal degradation of RNA, we used chloroquine (CQ), which is an established inhibitor of lysosomal enzymes,[@cit0020] in pulse-chase experiments ([Fig. 7A, lower panel](#f0007){ref-type="fig"}). If knockdown of *Sidt2* impairs lysosomal degradation of RNA, effect of CQ on RNA degradation should be decreased in *Sidt2*-knockdown cells. CQ treatment inhibited RNA degradation in control knockdown cells, whereas it did not inhibit it in *Sidt2*-knockdown cells ([Fig. 7E](#f0007){ref-type="fig"}). This result supports the notion that *Sidt2* knockdown impairs the lysosomal degradation of RNA in cells. In WT MEFs, knockdown of *Sidt2* inhibited ˜50% of total RNA degradation ([Fig. 7F--G](#f0007){ref-type="fig"}), and pulse-chase experiments using CQ confirmed that knockdown of *Sidt2* inhibits lysosomal degradation of RNA in these cells ([Fig. 7G](#f0007){ref-type="fig"}), suggesting that SIDT2-mediated RNA degradation, presumably RNautophagy, is a main pathway for constitutive lysosomal degradation of RNA in MEFs. Similar results were obtained when another siRNA against *Sidt2* (*Sidt2* siRNA-B) was used for knockdown ([Fig. 7H--L](#f0007){ref-type="fig"}). We confirmed that the macroautophagic flux, an indicator of activity of macroautophagy,[@cit0020] is not significantly changed by knockdown of *Sidt2* in WT MEFs ([Fig. 7M--N](#f0007){ref-type="fig"}). Thus, the effect of *Sidt2* knockdown is independent of macroautophagy, and *Sidt2* knockdown does not affect lysosomal enzymatic activity. Taken together, our findings indicate that SIDT2 is essential for normal levels of RNA degradation in cells, and strongly suggest that one of the physiological roles of RNautophagy is a constitutive degradation of cellular RNA. Figure 7.Effects of *Sidt2* knockdown on cellular RNA degradation. (A) Experimental paradigm for monitoring the degradation of cellular RNA. CQ, chloroquine. (B, F, H and K) Decreased levels of SIDT2 proteins in *atg5* KO MEFs and in WT MEFs transfected with *Sidt2*-siRNA were confirmed by immunoblotting. Mean ± SEM (*n* = 4). \*\*\*, *P* \< 0.001. \* indicates nonspecific bands which are not decreased by *Sidt2* knockdown. (C) RNA turnover in *atg5* KO MEFs cells, transfected as indicated, was measured as described in (A, upper panel) and Materials and Methods. Results are expressed as mean ± SEM (*n* = 4). \*\*\*, *P* \< 0.001, n.s., not significant, compared with 0 h. ^§§§^*P* \< 0.001, compared with time-matched control. In control and *Sidt2*-knockdown cells, 37.3 ± 0.6 and 21.1 ± 0.6 (mean ± SEM) % of RNA was calculated to be degraded during 24 h, respectively, and 20.9 ± 3.1 and 5.5 ± 1.3 (mean ± SEM) % during 6 h, respectively. (D) No conversion of MAP1LC3A/B-I to MAP1LC3A/B-II in *atg5* KO MEFs was confirmed by immunoblotting. (E) RNA turnover in *atg5* KO MEFs cells, transfected as indicated, with or without CQ was measured as described in (A, lower panel) and Materials and Methods. Mean ± SEM (*n* = 4). \*\*\*, *P* \< 0.001, n.s., not significant. In control and *Sidt2*-knockdown cells without CQ treatment, 40.1 ± 2.0 and 26.2 ± 0.6 (mean ± SEM) % of RNA was calculated to be degraded during 24 h, respectively. In control and *Sidt2*-knockdown cells with CQ treatment, 24.7 ± 2.0 and 20.9 ± 0.9 (mean ± SEM) % of RNA was calculated to be degraded during 24 h, respectively. (G) RNA turnover in WT MEFs, transfected as indicated, with or without CQ were measured as described in (E). Mean ± SEM (*n* = 4). \*\*\*, *P* \< 0.001, n.s., not significant. In control and *Sidt2*-knockdown cells without CQ treatment, 43.8 ± 2.6 and 21.8 ± 1.9 (mean ± SEM) % of RNA was calculated to be degraded during 24 h, respectively. Contribution of SIDT2 for total cellular RNA degradation was calculated to be 50.2%. In control and *Sidt2*-knockdown cells with CQ treatment, 23.7 ± 2.1 and 16.6 ± 1.8 (mean ± SEM) % of RNA was calculated to be degraded during 24 h, respectively. (I) RNA turnover in *atg5* KO MEFs cells, transfected as indicated, was measured as described in (C). Results are expressed as mean ± SEM (*n* = 4). \*\*\*, *P* \< 0.001; n.s., not significant, compared with 0 h. ^§§§^, *P* \< 0.001, compared with time-matched control. (J) RNA turnover in *atg5* KO MEFs cells, transfected as indicated, with or without CQ was measured as described in (E). Mean ± SEM (*n* = 4). \*\*\*, *P* \< 0.001, n.s., not significant. (L) RNA turnover in WT MEFs, transfected as indicated, with or without CQ were measured as described in (E). Mean ± SEM (*n* = 4). \*\*\*, *P* \< 0.001; n.s., not significant. (M and N) Macroautophagic flux assay was performed as described in Materials and Methods. Mean ± SEM (*n* = 3). n.s., not significant. (O) WT MEFs were transfected with siRNAs as indicated, and labeled with \[^3^H\]-uridine for 24 h. Then, acid-soluble radioactivity of cells was measured as described in Materials and Methods. Mean ± SEM (*n* = 4). \*\*\*, *P* \< 0.001.

Impaired RNA degradation may affect metabolic turnover of RNA, and thus alter cellular nucleotide or nuleoside levels. To assess whether knockdown of *Sidt2* affects the RNA-related nucleotide or nucleoside levels, we measured cellular uridine nucleotide or nucleoside levels using radioactive uridine. As shown in [Fig. 7O](#f0007){ref-type="fig"}, knockdown of *Sidt2* decreased the cellular uridine nucleotide or nucleoside levels, suggesting that SIDT2 and RNautophagy are important for normal cellular metabolism of RNA.

Discussion {#s0003}
==========

In the present study, we have found that SIDT2 mediates translocation of RNA into lysosomes during RNautophagy. The lysosomal membrane localization of SIDT2 may indicate that its main function is the translocation of RNA across the lysosomal membrane. At present, the precise mechanisms underlying the translocation of RNA across the lysosomal membrane have remained unclear. There are 2 possibilities that account for the translocation of RNA via SIDT2. The first possibility is that SIDT2 functions as an RNA transporter or channel. The second is that SIDT2 mediates deformations of the lysosomal membrane, such as a microautophagy-like process.

SID-1 contains 11 predicted transmembrane domains.[@cit0008] The N terminus of SID-1 protrudes into the extracellular space, while the C terminus is located in the cytosol.[@cit0008] SIDT2 was predicted to possess 9 transmembrane domains (Fig. S2). Consistent with the topology of SID-1, the N- and C-terminal domains of SIDT2 were predicted to be located in the lysosome and cytoplasm, respectively (Fig. S2). Results from a structural study showed that the extracellular domain of SIDT1 forms a stable tetrameric structure, which is characterized as "a compact, puck-shaped globular particle."[@cit0021] However, the mechanism of translocation for nucleic acids through SIDT proteins remains unclear. Structural studies of full-length SIDT1 and/or SIDT2 are required to clarify this issue.

We demonstrated that the mutant SIDT2^S564A^ is inactive in translocating RNA ([Fig. 4](#f0004){ref-type="fig"}). SIDT2 has been reported to be a putative hydrolase, and Ser564 appears to be important for this activity, because the corresponding serine residues are conserved among the transmembrane hydrolase superfamily, including known hydrolases.[@cit0022] Therefore, the putative hydrolase activity of SIDT2 is probably involved in mechanism of RNA transport and required for RNA transport during RNautophagy. Identification of the hydrolase activity of SIDT2 and its substrate should contribute to further understanding of the mechanisms underlying RNautophagy.

SID-1 has been reported to transport dsRNA and hairpin RNA containing both double- and single-stranded regions, but not short single-stranded RNA.[@cit0009] In the present study, we showed that SIDT2 translocates multiple mRNAs and rRNAs into lysosomes in vitro ([Fig. 2H--I](#f0002){ref-type="fig"}), indicating that SIDT2 is able to translocate single-stranded RNA. Whether or not SIDT2 translocates dsRNA into lysosomes is currently unclear.

Because SID-1 is a putative bidirectional channel for RNA,[@cit0009] it is possible that SIDT2 also mediates bidirectional transport of RNA. However, we assume that SIDT2 is not involved in the export of RNA from lysosomes because imported RNA would likely be degraded into nucleosides or nucleotides, and there are multiple transporters for nucleosides or nucleotides on the lysosomal membrane.[@cit0014] Degraded RNA might be exported from lysosomes by nucleoside or nucleotide transporters. In yeast, RNAs imported to vacuoles by macroautophagy are degraded into nucleosides, and then exported from vacuoles.[@cit0023]

A recent study showed that plasmid DNA can be imported into cultured silkworm cells by SID-1.[@cit0024] Considering that plasmid DNA is a substrate of DNautophagy in vitro,[@cit0004] it is possible that SIDT2 also mediates translocation of DNA during DNautophagy. Whether SIDT2 is involved in the transport of DNA is currently the subject of ongoing research.

We previously reported that the cytosolic region of LAMP2C directly binds to RNA, and that overexpression of LAMP2C enhances RNautophagy, indicating that LAMP2C can function as an RNA receptor during RNautophagy.[@cit0003] In the present study, we found that SIDT2 interacts with LAMP2C ([Fig. 1E--G](#f0001){ref-type="fig"}). Using LAMP2-deficient cells, however, we showed that SIDT2 is able to function independently of LAMP2C ([Fig. 3](#f0003){ref-type="fig"}). This is consistent with our previous report showing that RNautophagy activity is not completely abolished in lysosomes from *lamp2* KO mice.[@cit0003] Taken together, these results indicate that LAMP2 is not required for RNautophagy. We speculate that SIDT2 is more important than LAMP2C in the process of RNautophagy. At present, whether or not SIDT2 functions cooperatively with LAMP2C in the presence of LAMP2C is unclear.

In our current study, RNautophagy activities were detected in 5 different cell lines (Human HeLa, human 293FT, murine Neuro2a, murine NIH/3T3 and MEF), suggesting that RNautophagy occurs in wide variety of cells. These observations are consistent with the almost ubiquitous expression of SIDT2.[@cit0012]

In the present study, *Sidt2* knockdown inhibited ˜50% of total cellular RNA degradation in WT MEFs ([Fig. 7G](#f0007){ref-type="fig"}). Although RNAs can be degraded by exonucleases in the cytoplasm or nucleus,[@cit0025] we showed that the inhibition of RNA degradation in *Sidt2* knockdown cells is mainly due to impaired lysosomal degradation of RNA ([Fig. 7E, G, J and L](#f0007){ref-type="fig"}). Our results strongly suggest that RNautophagy is involved in cellular RNA degradation in mammalian cells, and one of the physiological roles of RNautophagy is the constitutive degradation of cellular RNA. Although late endosomal microautophagy[@cit0026] and macroautophagy could also mediate cellular RNA degradation, we showed that the effect of *Sidt2* knockdown on RNA degradation is independent of macroautophagy ([Fig. 7](#f0007){ref-type="fig"}). Considering that SIDT2 does not localize to late endosomes ([Fig. 1C](#f0001){ref-type="fig"}), the possibility that SIDT2 functions in late endosomal microautophagy is low. However, the possibility that *Sidt2* knockdown partly and indirectly affects late endosomal microautophagy at the cellular level cannot be completely excluded.

A recent study reports that targeted deletion of exon 2 of the *Sidt2* gene results in growth defects and glucose intolerance in mice.[@cit0027] These findings, together with the predominant localization of SIDT2 to lysosomes, strongly suggest that RNautophagy is essential for normal cell homeostasis. However, SIDT2 protein is not completely eliminated in the mice with deletion of exon 2 of the *Sidt2* gene,[@cit0027] suggesting that some splice variants of *Sidt2* are not deficient in these mice. Generation and investigation of complete *Sidt2*-deficient mice would contribute to further understanding of biological significance of SIDT2-mediated RNautophagy and SIDT2-mediated constitutive degradation of RNA.

Materials and methods {#s0004}
=====================

Plasmid generation {#s0004-0001}
------------------

The cDNAs encoding mouse SIDT2 and mouse SIDT1 were purchased from Open Biosystems-Thermo Scientific Inc.. (MMM1013-202769049 and MMM1013-202797985, respectively). DNA encoding human LAMP2C (NCBI reference sequence: NM_001122606) was synthesized by IDT, Inc. The cDNA encoding human *CTSB* was cloned from HeLa cells using reverse transcriptase PCR. For generation of pCI-neo-hLAMP2C, pCI-neo-mSIDT2 and pCI-neo-mSIDT1 vectors, each cDNA or synthetic DNA was amplified by PCR, and amplicons were subcloned into a pCI-neo mammalian expression vector (Promega, E1841) using XhoI and NotI recognition sites. We used specific primers to amplify mouse *Sidt2* (5′-AAA ACT CGA GCC GCC ACC ATG ATC GCC TGG CGT CTG CC-3′ and 5′-AAA AGC GGC CGC CTA GAA GAC ATA GAT CTT GTC CC-3′), mouse *Sidt1* (5′-AAA ACT CGA GCC GCC ACC ATG CTG GAC TGC CTG CGC CTG GCG-3′ and 5′-AAA AGC GGC CGC TCA GAA GAC AGG GAT CTG GTC TCT CCG-3′) and human *LAMP2C* (5′-AAA ACT CGA GCC GCC ACC ATG GTG TGC TTC CGC CTC TTC CC-3′ and 5′-AAA AGC GGC CGC TTA CAC AGA CTG ATA ACC AGT ACG AC-3′). To generate pCI-neo-mSIDT2-FLAG for the expression of SIDT2 with a FLAG tag at the C terminus, and pCI-neo-hLAMP2C-FLAG for the expression of LAMP2C with a FLAG tag at the hinge region (between Leu-350 and Arg-351), a DNA sequence encoding FLAG was inserted using the Quik-Change Mutagenesis Kit according to the manufacturer\'s instructions (Stratagene Inc.., 200518). A FLAG tag was fused to the C terminus of SIDT2, because SIDT2 possesses a signal peptide at the N terminus. We used specific primers to amplify *Sidt2-FLAG* (5′-AAA ACT CGA GCC GCC ACC ATG ATC GCC TGG CGT CTG CC-3′ and 5′-AAA AGC GGC CGC CTA CTT GTC ATC GTC GTC CTT GTA GTC GAA GAC ATA GAT CTT GTC CC-3′) and *LAMP2C-FLAG* (5′-GAC TAC AAG GAC GAC GAT GAC AAG AGG GTT CAG CCT TTC AAT GTG ACA C-3′ and 5′-CTT GTC ATC GTC GTC CTT GTA GTC TAG ATC AAA GGT ATT TAT CTG AAA-3′). For generation of pCI-neo-CTSB-FLAG for the expression of human CTSB with a FLAG tag at the C terminus, cDNA was amplified by PCR, and amplicons were subcloned into a pCI-neo using XhoI and NotI recognition sites. We used specific primers to amplify *CTSB* (5′-AAA ACT CGA GCC GCC ACC ATG TGG CAG CTC TGG GCC TCC C-3′ and 5′-AAA AGC GGC CGC TAC TTG TCA TCG TCG TCC TTG TAG TCG ATC TTT TCC CAG TAC TGA TCG GTG-3′). To generate pEGFP-mSIDT2 and pEGFP-mSIDT1 for expression of SIDT2 and SIDT1 with an EGFP tag at the C terminus, cDNA was amplified by PCR, and the amplicon was subcloned into pEGFP-N1 (Clontech, product number is unavailable) using XhoI and EcoRI or XhoI and BamHI recognition sites. We used *Sidt2*-specific primers (5′-AAA ACT CGA GCC GCC ACC ATG ATC GCC TGG CGT CTG CC-3′ and 5′-AAA AGA ATT CTG AAG ACA TAG ATC TTG TCC C-3′) and *Sidt1*-specific primers (5′-AAA ACT CGA GCC GCC ACC ATG CTG GAC TGC CTG CGC CTG GCG-3′ and 5′-AAA AGG ATC CCA GAA GAC AGG GAT CTG GTC TCT CCG-3′) for PCR amplification. Plasmids for the expression of the mutant SIDT2^S564A^ were constructed using the Quik-Change Mutagenesis Kit. All resulting constructs were confirmed by sequencing.

Cell culture and transfection {#s0004-0002}
-----------------------------

The human adenocarcinoma cell line HeLa, the mouse neuroblastoma cell line Neuro2a, the mouse fibroblast cell line NIH/3T3 and the human embryonic kidney cell line 293FT were maintained in Dulbecco\'s modified Eagle\'s medium (Gibco-Life Technologies, C11995500) supplemented with 10% fetal bovine serum (Sigma-Aldrich, 172012) at 37°C, 5% CO~2~. In this study, we used these 4 cell lines because they can be transfected easily, and to show that the experimental findings are not cell specific. We mainly used HeLa cells, because we previously showed that RNautophagy is active in this cell line.[@cit0003] Most of overexpression experiments ([Figs. 2, 4 and 6](#f0002 f0004 f0006){ref-type="fig"}) were performed with Neuro2a cells because mouse *Sidt2* and *Sidt1* cDNAs were used for overexpression. The *Atg5*-deficient (*atg5*^−/−^) mouse embryonic fibroblasts (MEFs), and WT MEFs (*Atg5*^+/+^) were kind gifts from Dr. Noboru Mizushima (The University of Tokyo, Tokyo, Japan), and maintained as described elsewhere.[@cit0028] The *LAMP2*-deficient HeLa cells were generated using the CRISPR/Cas9 system (PrecisionX Cas9 SmartNuclease Vector System, System Biosciences, CAS900A-1) according to the manufacturer\'s protocols. The target DNA sequence was 5\'-TCCGGGCTCAGGGCTCGTTC-3\' in exon 1 of the *LAMP2* gene. Transient transfection of cells with each vector was performed using Lipofectamine LTX with PLUS reagent (Life Technologies, 15338100) according to the manufacturer\'s instructions.

Immunofluorescence staining {#s0004-0003}
---------------------------

Cells grown on chamber slides were washed with phosphate-buffered saline (PBS; Life Technologies, C14190500BT) and fixed using 3.7% formaldehyde in PBS for 20 min at room temperature. Fixed cells were permeabilized with 0.1% (v/v) Tween 20 (Sigma-Aldrich, P1379) in PBS for 5 min, blocked with 3% bovine serum albumin (BSA; Iwai Chemicals, A001) in PBS for 1 h, and incubated with primary antibodies overnight at 4°C. After washing, cells were incubated with Alexa Fluor 594-conjugated secondary antibodies (Abcam, ab150108) for 1 h at room temperature, and slides were mounted with ProLong Gold antifade reagent (Life Technologies, P36934). Images were acquired using a confocal laser microscope (FV1000D IX81, Olympus, Tokyo, Japan) using a 60× oil immersion objective lens, and captured with Fluoview software (Olympus). The antibodies used were anti-EEA1 antibody (1G11; Abcam, ab70521), anti-RAB7A antibody (Rab7-117; Abcam, ab50533) and anti-MAP1LC3A/B antibody (4E12; MBL, M152-3). For labeling of lysosomes, cells were incubated with 100 nM LysoTracker Red DND 99 (Life Technologies, L-7528) in growth medium for 1 h, and fluorescence image acquisition was performed with a FLUOVIEW FV10i confocal microscope (Olympus, Tokyo, Japan). Quantification and calculation of colocalization rates were performed using ImageJ software version 1.46r (National Institutes of Health) via the JACoP Plugin as described in the literature.[@cit0029]

Immunoprecipitation and immunoblotting {#s0004-0004}
--------------------------------------

Immunoprecipitation was performed as described previously,[@cit0030] with slight modifications. Briefly, cells or whole mouse brains were lysed or homogenized in lysis buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100 (Sigma-Aldrich, T8787) and protease inhibitors (Complete, EDTA-free; Roche Diagnostics, 11873580001) at 4°C. Lysates were centrifuged at 20,000 × g for 10 min at 4°C, and the supernatant fractions were immunoprecipitated using Anti-FLAG M2 Affinity Gel (Sigma-Aldrich, A2220) or primary antibodies as listed below. The primary antibodies used for immunoprecipitation or immunoblotting were: polyclonal goat anti-SIDT2 (N-20; Santa Cruz Biotechnology, sc-54151), polyclonal goat anti-SIDT1 (GeneTex, GTX88799), monoclonal rat anti-LAMP2 (M3/84; Santa Cruz Biotechnology, sc-19991), monoclonal mouse anti-DYKDDDDK (FLAG; Wako Pure Chemical Industries, 018-22783), monoclonal rabbit anti-SCARB2/LIMP2 (EPR12080; Abcam, ab176317), monoclonal mouse anti-RAB7A (Rab7-117; Abcam, ab50533), monoclonal mouse anti-RAB5A (RAB5A, member RAS oncogene family) (D-11; Santa Cruz Biotechnology, sc-46692), monoclonal mouse anti-MAP1LC3A/B (4E12; MBL, M152-3), polyclonal rabbit anti-LMNA (lamin A) (H-102; Santa Cruz Biotechnology, sc-20680), monoclonal mouse anti-COX4I1 (cytochrome c oxidase subunit IV isoform 1) (20E8C12; Life Technologies, A21348), monoclonal mouse anti-GOLGA1/Golgin-97 (CDF4; Life Technologies, A-21270), polyclonal rabbit anti-CANX (calnexin) (Abcam, ab22595), monoclonal mouse anti-GAPDH (6C5; Merck Millipore, CB1001), polyclonal rabbit anti-TUBB (tubulin, β)/β-tubulin (Cell Signaling Technology, 2146), and monoclonal mouse anti-ACTB/β-actin (AC-15; Sigma-Aldrich, A5441). The rabbit polyclonal anti-LAMP2C antibody was prepared as described previously.[@cit0003] The rabbit polyclonal anti-SIDT2 antibody was raised in a rabbit against synthetic peptides (C+STWQKTPAESREHNR) containing an amino acid sequence corresponding to the C-terminal region of SIDT2. The specificity of the rabbit anti-SIDT2 antibody was confirmed as shown in Fig. S7D. The polyclonal goat anti-SIDT2 antibody was used for detection of murine SIDT2, while the polyclonal rabbit anti-SIDT2 antibody was used to detect human SIDT2. Following overnight incubation with primary antibodies at 4°C, each blot was probed with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Thermo Scientific, 31460), anti-mouse IgG (Thermo Scientific, 31430) anti-goat IgG (Jackson ImmunoResearch, 305-036-003), or anti-rat IgG antibodies (Jackson ImmunoResearch, 112-035-003). In some experiments, the Can Get Signal Immunoreaction Enhancer Solution (Toyobo, NKB101) was used. Immunoreactive signals were visualized using the SuperSignal West Dura extended duration substrate (Thermo Scientific, 34075) and detected with a chemiluminescence imaging system (ImageQuant LAS 4000; Fujifilm). Signal intensity was quantified using ImageJ software.

RNA interference {#s0004-0005}
----------------

For siRNA-mediated knockdown of *SIDT2* or *Sidt2*, cells were transfected with 10 nM of *SIDT2*- or *Sidt2*-targeting, or control siRNAs using Lipofectamine RNAiMAX (Life Technologies, 13778075) for 72 h. The interference efficiency was evaluated by immunoblotting. The target sequences are 5′-GAG GAU GAC UAC GAC ACA U-3′ (human *SIDT2* siRNA-A), 5′-CUA UGG UUG CAU UUC CGU U-3′ (human *SIDT2* siRNA-B), 5′-CAG CAC GAC UUC UUC AAG U-3′ (*EGFP* siRNA for human cells[@cit0031]), 5′-GUU CUG UGU UAG UCA CGU A-3′ (mouse *Sidt2* siRNA-A), 5′-GAG UUU CCG UCC AGU AUU U-3′ (mouse *Sidt2* siRNA-B), and 5′-GCC ACA ACG UCU AUA UCA U-3′ (*EGFP* siRNA for mouse cells[@cit0032]). *EGFP* siRNAs were used as a control.

Total RNA isolation {#s0004-0006}
-------------------

Total RNA from cultured cells or mouse brains was isolated using TRIzol Reagent (Life Technologies, 15596-018) and quantified with a NanoDrop1000 analyzer (Thermo Scientific, Waltham, MA, USA). Total RNA that does not contain small RNAs was isolated using ISOGEN II (Nippon Gene, 311-07361). All animal experiments were approved by the animal experimentation committee of the National Center of Neurology and Psychiatry.

Uptake and degradation of RNA by isolated lysosomes {#s0004-0007}
---------------------------------------------------

RNA uptake and degradation was assessed using a cell-free system of intact lysosomes as described previously.[@cit0003] Briefly, lysosomes were isolated from mouse brains or from cultured cells by density gradient centrifugation. Isolated lysosomes (25 to 50 µg of protein) were incubated with 5 µg of total RNA derived from mouse brains at 37°C for 5 min in 30 µl of 0.3 M sucrose (Sigma-Aldrich, 28-0010-5) containing 10 mM MOPS buffer (pH 7.0) with an energy regeneration system (10 mM ATP, 10 mM MgCl~2~, 2 mM phosphocreatine, and 5 µg/ml creatine phosphokinase). For uptake assays, lysosomes were precipitated by centrifugation after the reaction, and RNA levels remaining in the supernatant were analyzed by agarose gel electrophoresis with ethidium bromide staining and UV illumination. In parallel, to directly assess the levels of RNA taken up by lysosomes, RNA outside of lysosomes was degraded by adding 30 µl of 0.3 M sucrose containing 10 μg of RNase A (Qiagen, 19101) to the precipitated lysosomes. RNase A treatment was carried out for 30 min at 4°C, and then RNA was extracted using TRIzol. The levels of RNase A-resistant RNA were analyzed by agarose gel electrophoresis. For degradation assays, RNA was extracted using TRIzol after the reaction, and the total levels of RNA in the samples were analyzed.

Measurement of RNA degradation {#s0004-0008}
------------------------------

RNA degradation in WT MEFs and *atg5* KO MEFs was measured as described previously,[@cit0033] with slight modifications. Cells grown in 24-well culture plates were transfected with *Sidt2* or control siRNAs for 48 h, and then 0.3 µCi/ml (˜0.012 pM) \[^3^H\]-uridine (PerkinElmer, NET367001MC) was added to the culture medium to label RNA in cells (pulse). After 24 h of labeling (72 h post-transfection), cells were washed with 500 µl of growth medium containing 5 mM unlabeled uridine (excess amount of uridine compared with \[^3^H\]-uridine), and incubated in another 500 µl of the same medium (chase). After 0, 6 and 24 h of incubation, cells were trypsinized and acid-insoluble radioactivity was measured using a liquid scintillation counter (Tri-Carb 3100TR; PerkinElmer, Waltham, MA, USA). In some experiments, cells were treated with chloroquine (CQ; 50 µM) in the chase medium for 0 or 24 h ([Fig. 7E, G, J and L](#f0007){ref-type="fig"}). Radioactivity was normalized to levels of total proteins, and expressed as percentage of radioactivity at 0 h in control- or *Sidt2*-siRNA transfected cells. From radioactivity at 0 h, the weight of \[^3^H\]-uridine that was incorporated into RNA was calculated to be under 0.02% (w/w) of the weight of total RNA. Therefore, reincorporation of \[^3^H\]-uridine into RNA during the chase is negligible. RNA degradation rate (%) was calculated by subtracting the relative acid-insoluble radioactivity (% of 0 h) from 100% (relative acid-insoluble radioactivity at 0 h). Contribution of SIDT2 for total cellular RNA degradation (%) was calculated by the formula SIDT2 contribution (%) = (RNA degradation rate in control cells (%) - RNA degradation rate in *Sidt2*-knockdown cells (%)) / RNA degradation rate in control cells (%) × 100. Measurement of cellular nucleotide or nucleoside levels was performed as described in the literature[@cit0034] with some modifications. Cells were transfected with siRNAs, labeled with \[^3^H\]-uridine for 24 h and washed as described above. Then, acid-soluble radioactivity of cells was measured, and normalized to levels of total proteins.

Electron microscopy {#s0004-0009}
-------------------

Electron microscopy was performed as previously described.[@cit0003] To observe their morphology, isolated lysosomes were fixed with 2.5% glutaraldehyde in phosphate buffer (pH 7.2) overnight at 4°C, and postfixed with 1% osmium for 1 h at room temperature. Samples were then dehydrated using a series of water/ethanol mixtures up to 100% ethanol, and embedded in Epon (Nisshin EM Co., Ltd., 3402). The embedded samples were sectioned at 70 nm, collected on 400-mesh copper grids (Nisshin EM Co., Ltd., 2507), and observed under a Tecnai Spirit transmission electron microscope (FEI Company, Eindhoven, The Netherlands) at 120 kV.

For immunogold electron microscopy, isolated lysosomes were fixed in 0.1% glutaraldehyde and 4% paraformaldehyde in PBS overnight at 4°C. Samples were then dehydrated in a series of water/ethanol mixtures up to 100% ethanol, and embedded in LR White (Nisshin EM Co., Ltd., 3962). The embedded samples were sectioned at 100 nm, and collected on 400-mesh nickel grids coated with collodion (Nisshin EM Co., Ltd., custom-made). Immunogold labeling was performed using an anti-rRNA antibody (Y10b; Abcam, ab37144) followed by anti-mouse IgG coupled with 10-nm gold particles (GE Healthcare, RPN431V), and viewed using a Tecnai Spirit transmission electron microscope at 80 kV. The Y10b antibody specifically recognizes several different rRNAs from diverse species, including 28S, 18S and 5.8S rRNAs.[@cit0036]

Quantitative PCR (qPCR) {#s0004-0010}
-----------------------

We reverse transcribed 1 μg of total RNA using a QuantiTect Reverse Transcription Kit (Qiagen, 205311) in a final volume of 20 µl, according to the manufacturer\'s instructions. For qPCR assays, an Mx3000P qPCR System (Stratagene) and SYBR Premix ExTaq II (Takara Bio Inc.., RR820) were used. We used primers specific for mouse *Actb*/β-actin (5′-CGT GCG TGA CAT CAA AGA GAA-3′ and 5′-CAA TAG TGA TGA CCT GGC CGT-3′), mouse *Gapdh* (5′-TGT CAA GCT CT TTC CTG GTA TG-3′ and 5′-TTA TGG GGG TCT GGG ATG GA-3′), mouse *Uchl1* (5′-TTT TTC GGC TCC TCG GGT TT-3′ and 5′-TGG CCA ACA CTT TGT TCA GC-3′), mouse 5S rRNA (5′-GTC TAC GGC CAT ACC ACC C-3′ and 5′-AAG CCT ACA GCA CCC GGT ATT-3′), and mouse 5.8S rRNA (5′-GGT GGA TCA CTC GGC TCG T-3′ and 5′-GCA AGT GCG TTC GAA GTG TC-3′). Test samples were assayed in 20-µl reactions comprising 10 µl of Premix, 0.5 µM primers, 2 µl of cDNA and 6 µl of nuclease-free H~2~O. Nontemplate controls were also included. The thermal cycling profile consisted of an initial denaturation step (30 s at 95°C), followed by 40 cycles of amplification (95°C for 5 s 60°C for 30 s). Following amplification, melting curve analysis was performed to verify the authenticity of the amplified product and determine its specific melting temperature.

Macroautophagic flux assay {#s0004-0011}
--------------------------

Macroautophagic flux assay was performed as described in the literature.[@cit0020] Briefly, WT MEFs were transfected with siRNA. Forty-eight h after the transfection, cells were incubated with or without 50 µM CQ for 4 or 24 h. Then, cell lysates were prepared and subjected to immunoblotting, and relative levels of MAP1LC3A/B-II and TUBB/β-tubulin were quantified. MAP1LC3A/B-II levels were normalized by TUBB levels. Macroautophagic flux was calculated by subtracting the normalized MAP1LC3A/B-II levels in CQ- samples from the levels in CQ+ samples.

Statistical analysis {#s0004-0012}
--------------------

We used the Student *t* test for the comparison of 2 sets of data. For comparison of more than 2 groups, analysis of variance (ANOVA) with the Tukey multiple comparison test was used, unless otherwise mentioned.
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